TY - JOUR
T1 - Aptamer-mediated liver-targeted curcumin delivery system based on tetrahedral framework nucleic acids for NAFLD
AU - Chen, Shaoyun
AU - Liu, Yuchen
AU - Ma, Siying
AU - Chen, Lin
AU - Zhou, Liping
AU - Wang, Jiawen
AU - Huang, Yingying
AU - Yu, Zhiling
AU - Dou, Xiaobing
N1 - The authors thank financially support from the Basic Public Welfare Research Program of Zhejiang Province (No. LTGY23H290002), National Natural Science Foundation of China (No. 81603254; No. 82374102), Leading Talents + X Program of Zhejiang Province (No. 2025C02174).
Publisher Copyright:
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025/12/31
Y1 - 2025/12/31
N2 - Curcumin is renowned for anti-inflammatory, antioxidant and hepatoprotective effects, and has been implicated in the amelioration of obesity and diabetes. Notwithstanding its considerable therapeutic potential, the clinical utility of curcumin is hampered by its suboptimal bioavailability, due to poor aqueous solubility and chemical instability. Consequently, the development of strategies to enhance the aqueous solubility, stability, and ultimately, the bioavailability of curcumin has been a focal point of intense research. This study harnessed tetrahedral framework nucleic acids (tFNAs), a relatively simple DNA nanostructure, to encapsulate curcumin. Meanwhile, novel aptamers for liver-specific targeting were acquired by SELEX (Systematic Evolution of Ligands by Exponential Enrichment) method. By capitalizing on the unique properties of aptamers and tFNAs, an aptamer-mediated liver-targeted curcumin delivery system was constructed, with the goal of providing a more efficacious therapeutic approach for non-alcoholic fatty liver disease (NAFLD). This innovative delivery platform has not only markedly improved the solubility and stability of curcumin but has also significantly bolstered its therapeutic efficacy in the context of NAFLD. This research not only offers a novel approach for the delivery of curcumin but also presents a new therapeutic modality for NAFLD. Moreover, the implications of this research extend beyond curcumin, offering a blueprint for the liver-targeted delivery of other drug molecules.
AB - Curcumin is renowned for anti-inflammatory, antioxidant and hepatoprotective effects, and has been implicated in the amelioration of obesity and diabetes. Notwithstanding its considerable therapeutic potential, the clinical utility of curcumin is hampered by its suboptimal bioavailability, due to poor aqueous solubility and chemical instability. Consequently, the development of strategies to enhance the aqueous solubility, stability, and ultimately, the bioavailability of curcumin has been a focal point of intense research. This study harnessed tetrahedral framework nucleic acids (tFNAs), a relatively simple DNA nanostructure, to encapsulate curcumin. Meanwhile, novel aptamers for liver-specific targeting were acquired by SELEX (Systematic Evolution of Ligands by Exponential Enrichment) method. By capitalizing on the unique properties of aptamers and tFNAs, an aptamer-mediated liver-targeted curcumin delivery system was constructed, with the goal of providing a more efficacious therapeutic approach for non-alcoholic fatty liver disease (NAFLD). This innovative delivery platform has not only markedly improved the solubility and stability of curcumin but has also significantly bolstered its therapeutic efficacy in the context of NAFLD. This research not only offers a novel approach for the delivery of curcumin but also presents a new therapeutic modality for NAFLD. Moreover, the implications of this research extend beyond curcumin, offering a blueprint for the liver-targeted delivery of other drug molecules.
KW - aptamer
KW - Curcumin
KW - NAFLD
KW - tetrahedral framework nucleic acids
UR - https://www.scopus.com/pages/publications/105021200711
UR - https://www.tandfonline.com/doi/full/10.1080/10717544.2025.2576222#abstract
U2 - 10.1080/10717544.2025.2576222
DO - 10.1080/10717544.2025.2576222
M3 - Journal article
C2 - 41208249
AN - SCOPUS:105021200711
SN - 1071-7544
VL - 32
JO - Drug Delivery
JF - Drug Delivery
IS - 1
M1 - 2576222
ER -